Impact of cannabinoids on cancer outcomes in patients receiving immune checkpoint inhibitor immunotherapy
MariaLuisa Vigano,
No information about this author
Lixing Wang,
No information about this author
Alia As’sadiq
No information about this author
et al.
Frontiers in Immunology,
Journal Year:
2025,
Volume and Issue:
16
Published: March 5, 2025
Cannabinoids
relieve
pain,
nausea,
anorexia
and
anxiety,
improve
quality
of
life
in
several
cancer
patients.
The
immunotherapy
with
checkpoint
inhibitors
(ICIs),
although
very
successful
a
subset
patients,
is
accompanied
by
moderate
to
severe
immune-related
adverse
events
(ir-AE)
that
often
necessitate
its
discontinuation.
Because
their
role
symptomatic
relief,
cannabinoids
have
been
used
combination
immune
inhibitor
(ICI)
immunotherapy.
A
few
studies
strongly
suggest
the
use
medicinal
cannabis
patients
attenuates
many
ir-AE
associated
ICI
increase
tolerability.
However,
no
significant
beneficial
effects
on
overall
survival,
progression
free
survival
or
relapses
were
observed;
rather,
some
noted
concurrent
administration
clinical
benefits
latter.
cannabinoids'
well
documented
immunosuppressive
mediated
through
cannabinoid
recptor-2
(CB2),
we
propose
considering
this
receptor
as
an
inhibitory
per
se.
simultaneous
neutralization
CB2,
treatment,
may
lead
better
outcomes
receiving
In
regard,
such
cannabidiol
(CBD)
cannabigerol
(CBG),
little
agonism
for
be
therapeutic
choices.
Additional
strategies
e.g.,
monoacylglycerol
lipase
(MAGL)
degrade
endocannabinoids
lipogenesis
formation
lipid
bilayers
cells
also
explored.
Future
should
take
into
consideration
gut
microbiota,
CYP450
polymorphism
haplotypes,
cannabinoid-drug
interactions
genetic
somatic
variations
occurring
receptors
signaling
pathways
personalized
cannabis-based
therapies
ICIs.
This
rational
knowledge-based
regimens
tailored
individual
Language: Английский
Emerging autism and Fragile X syndrome treatments
Trends in Pharmacological Sciences,
Journal Year:
2025,
Volume and Issue:
unknown
Published: March 1, 2025
Language: Английский
Cannabidiol reverses myeloperoxidase hyperactivity in the prefrontal cortex and striatum, and reduces protein carbonyls in the hippocampus in a ketamine-induced schizophrenia rat model
Schizophrenia Research,
Journal Year:
2025,
Volume and Issue:
278, P. 82 - 95
Published: March 25, 2025
Language: Английский
Investigation in the CB1 and CB2 receptor binding profile and intrinsic activity of (-) and (+)-enantiomers of some naturally occurring phytocannabinoids or synthetic derivatives
European Journal of Medicinal Chemistry Reports,
Journal Year:
2025,
Volume and Issue:
unknown, P. 100262 - 100262
Published: April 1, 2025
Language: Английский